The Experimental Cellular Pathology Core is designed to provide investigators with centralized pathologic services, including immunohistochemical (IHC) and flow cytometric (FCM) procedures in support of all four projects. This resource combines the expertise and facilities of the UAMS Department of Pathology with those of the Myeloma Institute for Research and Therapy. Centralizing these core services will avoid the need for each investigator to establish them in their own laboratories and will have the added benefit of providing for uniformity of procedures and efficient use of materials and capitol equipment. The core will address the following specific aims:
Specific Aim 1 : Provide pathology services to investigators in each P01 project. Specifically, this will include IHC and laser capture microdissection (LCM). IHC services will be performed on patient samples provided by Project 1 and utilized in support of Projects 1, 2 and 3 as well as on in vivo animal model studies in Projects 2 and 4. A major advantage of tissue section IHC is that the topography of the tissue remains intact and morphologic and immunologic features can be integrated to allow for microanatomic analysis of the bone marrow architecture. LCM services will be instrumental in Projects 1 and 4 where studies will examine focal and interstitial disease patterns as well as the marrow microenvironment.
Specific Aim 2 : Construct tissue microarrays (TIVIAs). A central aspect of the core will be the construction of TMAs using material derived from new patients as well as patients enrolled onto treatment protocols in Project 1. Gene expression profiling and proteomics play central roles in the POI and by using materials such as the TMAs, Core E will provide an important function by assisting Project 1, in conjunction with Core C, in the validation of key genes and proteins relating to the tumor cell/bone marrow microenvironment identified through these technologies.
Specific Aim 3 : Provide flow cytometry services to validate novel markers of minimal residual disease monitoring, and for characterization and identification of myeloma subpopulations with distinct genetic and biologic properties. The relatively recent identification of aberrant immunophenotypes in malignant plasma cells and the unique ability of to identify and characterize even minor cellular subpopulations makes FCM an ideal technology to accomplish the goals delineated in Project 1. FCM will also be useful for the immunophenotypic characterization of the expanded NK cell preparations that will be developed in Project 2.

Public Health Relevance

While gains have been made, myeloma remains a difficult cancer to treat and manage. Mounting evidence indicates that the bone marrow microenvironment plays an important role in the growth and dissemination of myeloma, as well as myeloma bone disease. The mechanisms governing focal tumor growth, in the context of diffuse disease, are not understood. A major goal of this Pathology Core (Core E) is to provide comprehensive, meaningful pathology support services to project investigators addressing these issues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-18
Application #
8555176
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
2000-06-05
Project End
2014-08-31
Budget Start
2012-09-11
Budget End
2013-08-31
Support Year
18
Fiscal Year
2012
Total Cost
$202,306
Indirect Cost
$62,714
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867

Showing the most recent 10 out of 284 publications